Wolff-Parkinson-White syndrome presenting in atrial fibrillation

Schatz, Ivan; Ordog, Gary J.; Karody, Ramesh; Bhasin, Vijay

doi:10.1016/s0196-0644(87)80691-1

Cited by 11 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This type of syncopal episode that is secondary to cardiac arrhythmias, known as Stokes-Adams attack, can be fatal. 22 Although it is possible that the co-occurrence of myotonia congenita and Wolff-Parkinson-White syndrome in the same patient is coincidental, it is also plausible that both entities, which respectively affect skeletal muscular tissue and cardiac conduction, are connected as a consequence of a shared causal FIGURE 2. Anderson described a patient with probable Thomsen disease, who presented with second-degree heart block with Wenckebach phenomenon.…”

Section: Discussionmentioning

confidence: 99%

Becker Myotonia Congenita Associated WithWolff-Parkinson-WhiteSyndrome

Caballero¹

2011

The Neurologist

View full text Add to dashboard Cite

Becker's disease is a congenital myotonia with an autosomal recessive pattern of inheritance. Unlike myotonic dystrophy, it is not associated with cardiopathy. We present a 32-year-old man with Becker's disease diagnosed at age 11. He suffered episodes of loss of consciousness preceded by palpitations when he performed strenuous physical exercise. The electrocardiogram reveals a Wolff-Parkinson-White syndrome. Review of the literature in MEDLINE using the search terms of congenital myotonia or Becker's disease and arrhythmia or heart disease only found 2 articles on Thomsen disease but none on Becker's disease. Becker's myotonia congenita may exceptionally be associated with cardiopathy, thus patients with this disorder should have a cardiac evaluation.

show abstract

Section: Discussionmentioning

confidence: 99%

Becker Myotonia Congenita Associated WithWolff-Parkinson-WhiteSyndrome

Caballero¹

2011

The Neurologist

View full text Add to dashboard Cite

show abstract

“…The study concludes that procainamide administration increases the antegrade effective refractory period and the intra-atrial conduction time significantly [6]. Schatz et al support procainamide as the favored pharmacological treatment for patients with WPW-AF due to the ability to safely lengthen the effective refractory period [12]. Additionally, Fengler et al [4] favor the use of procainamide in WPW-AF, stating procainamide prolongs the effective refractory period and slows antegrade and retrograde conduction in the AP.…”

Section: Discussionmentioning

confidence: 99%

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation

et al. 2010

View full text Add to dashboard Cite

The objective of this review is to explore and challenge the superiority of amiodarone for rate control in Wolff-Parkinson-White syndrome and concomitant atrial fibrillation (WPW-AF). The current recommendation for pharmacological treatment of this condition is amiodarone. A review of the past 25 years of literature finds several studies that identify a small risk of ventricular fibrillation secondary to amiodarone administration for rate control in WPW-AF. Additionally, the literature supports the safe and effective use of procainamide for rate control in WPW-AF. This review concludes that amiodarone is not superior to procainamide in rate control for WPW-AF, and may be dangerous.

show abstract

“…Treatment of AF associated with WPW is completely different [96]. The basic treatment principle in WPW AF is to prolong the anterograde refractory period of the accessory pathway relative to the AV node to slow the rate of impulse transmission through the accessory pathway and, thus, the ventricular rate.…”

Section: Symptomatic Patientsmentioning

confidence: 99%

Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update

Vătășescu,

Paja,

Șuș

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Wolf–Parkinson–White (WPW) syndrome is a disorder characterized by the presence of at least one accessory pathway (AP) that can predispose people to atrial/ventricular tachyarrhythmias and even sudden cardiac death. It is the second most common cause of paroxysmal supraventricular tachycardia in most parts of the world, affecting about 0.1–0.3% of the general population. Most patients with WPW syndrome have normal anatomy, but it may be associated with concomitant congenital heart disease or systemic diseases. Although many individuals are asymptomatic, during supraventricular arrhythmia episodes, they may experience severe symptoms, including syncope or even sudden cardiac death (mainly due to pre-excited atrial fibrillation over rapidly conducting AP). In addition to arrhythmia-related symptoms, for some specific locations of the APs with overt anterograde conduction, there might be a reduction in exercise capacity mediated by a reduction in LV systolic performance due to anomalous LV depolarization. Although it is typically diagnosed through electrocardiography (ECG), additional tests are necessary for risk assessment. Management of WPW syndrome may be quite challenging and can vary from only acknowledging the presence of the accessory pathway to pharmacological treatment or radiofrequency ablation. Early diagnosis, risk assessment, and appropriate treatment are critical steps in the management of WPW syndrome, aiming to improve the quality of life and reduce the risk of life-threatening arrhythmias.

show abstract

Wolff-Parkinson-White syndrome presenting in atrial fibrillation

Cited by 11 publications

References 21 publications

Becker Myotonia Congenita Associated WithWolff-Parkinson-WhiteSyndrome

Becker Myotonia Congenita Associated WithWolff-Parkinson-WhiteSyndrome

Challenging the superiority of amiodarone for rate control in Wolff-Parkinson-White and atrial fibrillation

Wolf–Parkinson–White Syndrome: Diagnosis, Risk Assessment, and Therapy—An Update

Contact Info

Product

Resources

About